These results raise the importance of evaluating, particularly in diffuse-type GC, the expression of FGFR2-IIIc, rather than FGFR2-IIIb or total FGFR2. Therefore, we believe FGFR2-IIIc should be explored as a molecular target for patients with diffuse-type GC, also providing an opportunity to repurpose available anti-FGFR2-IIIc therapies. The gene discussed is FGFR2; the disease is gastric cancer.